Sign in
Active, not recruitingNo phase

Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)

Key facts

Who runs it
PharmaBio Corporation
Where
Japan2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
10 people, planned
Started
17 Feb 2023
Expected to end
30 Sept 2027
Type of study
Interventional
Treatments tested
  • Pars plana vitrectomy
Record updated
29 September 2026

Who can take part

Age
20 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Patients aged 20 years or older at the time of consent acquisition
  • Patients with binocular intensity myopia (myopia of -6.0 diopter (D) or more) or patients with axial length (26 mm) or more equivalent to -6.0 D
  • Corrected characters of the test eye patients with visual acuity of less than 60 characters (equivalent to decimal visual acuity 0.32)
  • Patients diagnosed with binocular myopic chorioretinal atrophy and having atrophy of 1 papillary diameter (1.5 mm) or more in the area within 2 papillary diameter (3.0 mm) including the fovea centralis in the subject eye
  • Patients without active choroidal neovascularization

Who cannot take part

  • Patients who cannot discontinue anticoagulants or antiplatelet drugs before the trial
  • Patients with drug addiction or alcoholism
  • Patients receiving treatment with vascular endothelial growth factor inhibitor or photodynamic therapy within 4 months prior to transplantation for test eye or 2 months for reference eye
  • Patients who underwent eye surgery (excluding lens reconstruction) within 3 months before transplantation. In the case of cataract surgery, if 7 days or more have passed since surgery and postoperative inflammation is stable, registration is possible
  • Patients with eye infections
  • Patients with other retinal diseases (diabetic retinopathy, hypertensive retinopathy, vascular occlusion)
  • Patients with findings associated with myopic traction macular disease (apparent posterior macular tumor, vitreous macular traction, retinal separation, macular hole detachment, macular hole)
  • Patients with severe blood disorders, heart failure, liver disorders, and renal disorders
  • Patients diagnosed with malignant tumor within 5 years or patients requiring treatment
  • Patients with positive hepatitis B surface (HBs) antigen, Hepatitis C virus (HCV) antibody, Human immunodeficiency virus (HIV) antibody, Human T-lymphotropic virus type 1 (HTLV-1) antibody, syphilis serum reaction
  • Patients with allergies to human serum albumin antibiotics, trypsin
  • Patients with abnormal findings that pose a problem in clinical trial participation in screening tests
  • Patients with confirmed optic nerve atrophy
  • Patients with glaucoma who cannot control intraocular pressure
  • Patients with atrophy in all areas of the circle within 3 papilla diameter (4.5 mm) (9.0 mm in diameter) from the fovea
  • Patients with corrected visual acuity of control eye 0.08 or less
  • Pregnant women, lactating women, patients wishing to become pregnant during the trial period

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to assess efficacy and safety in patients with myopic chorioretinal atrophy.

Read full original descriptionShow less

The main question it aims to answer are:

• Percentage of changes in the chorioretinal atrophic area

Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy.

Researchers will compare non-therapeutic eye to see if the changes is significant different.

The group in the trial

  • therapeutic groupTreatment being tested

    Treatment: Pars plana vitrectomy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)
Publications
Record updated
29 September 2026